#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

#### CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 10, 2022

LANDEC CORPORATION

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 000-27446 (Commission file number) 94-3025618 (IRS Employer Identification No.)

93455

(Zip Code)

2811 Airpark Drive

Santa Maria, California (Address of principal executive offices)

(650) 306-1650

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Common Stock

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

D Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

D Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: Title of each class

Trading Symbol LNDC

Name of each exchange on which registered The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  $\Box$ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### Item 7.01 Regulation FD.

On January 10, 2022, Landec Corporation, a Delaware corporation (the "Company") will be presenting at the 2022 ICR Conference. A copy of the Company's presentation materials (the "Presentation") is attached hereto as Exhibit 99.1 and is incorporated by reference in this Item 7.01.

The foregoing information in this Item 7.01, including the information contained in the Presentation in Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not incorporated by reference into any of the Company's filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibit.

The following exhibits are furnished as part of this report:

Exhibit No.	Description
<u>99.1</u>	ICR Conference 2022 Presentation
104	Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 10, 2022

#### LANDEC CORPORATION

By: /s

/s/ John D. Morberg John D. Morberg Chief Financial Officer

3



## Important Information Regarding Forward-Looking Statements



This presentation contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as "anticipate", "estimate", "potential," "target," "expect", "project", "plan", "intend", "believe", "may", "might", "will", "should", "can have", "likely" and similar expressions are used to identify forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, as the timing and expenses associated with operations, the ability to achieve acceptance of the Company's new products or obtain arrangements with new customers in the market place, the timing and ability to obtain regulatory approvals (including by us and our customers), government regulations affecting our business, the ability to maintain and grow existing client relationships and manage expenses, uncertainties related to COVID-19 and the impact of our responses to it. For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the Securities and Exchange Commission, including the risk factors contained in our most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K. Forward-looking statements represent management's current expectations and are inherently uncertain. We do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances that may arise after the date of this presentation.

## **Lifecore Business Highlights**



Fully-integrated CDMO with **highly differentiated capabilities** for development and fill/finish of sterile, injectable-grade pharmaceutical products



A leading provider of premium research grade HA with focus on complex and highly regulated products



Large, growing addressable markets with attractive underlying tailwinds supported by long-term customer relationships and low turnover



Aspirational goal to accelerate annual revenue growth into the mid- to high-teens based upon current pipeline characteristics and favorable industry tailwinds in the coming years



Multiple levers to continue to drive **long-term growth**, including continued **expansion and commercialization** of development pipeline



Ø

35+ years of exceptional quality, safety, and regulatory compliance with available capacity & state-of-the-art facilities to support future growth



Highly experienced Lifecore management team with deep industry expertise and proven ability to execute



# **Growth Strategies**



1	EXPANSION OF DEVELOPMENT PIPELINE AND COMMERCIAL SERVICES	2. TARGET INCREASING OPERATIONAL CAPACITY
pip Ta Ide Ide	vest in people and systems to support expanded development beline and services argeted sales and marketing strategy entify and expand development services portfolio entify late phase development and new commercial portunities	<ul> <li>Invest in people &amp; systems to seek to maximize efficiencies and growth potential</li> <li>Advance late phase development projects through commercialization</li> <li>Advance early phase projects and support commercial growth of marketed products</li> <li>Support commercial growth of base business</li> <li>Identify strategic adjacencies and partnerships</li> <li>Target increasing operational capacity to 22 million units by FY25 and 45 million units by FY28</li> </ul>



## State-Of-The-Art Manufacturing Sites







Four ISO 5 clean rooms with various fillers supported by five ISO 7 formulation rooms



Dedicated Development and Pilot Labs



Three analytical labs supporting development and commercial testing/stability







Lifecore also has an FDA approved warehouse site with 21,400sq. ft.

Invested \$100M during the past 10 years and \$58M over the last 3 years (FY20-22) in capital expenditures related to innovation, product development, facilities, equipment and new capabilities for the Lifecore business



# **Highly Differentiated End-To-End Capabilities**






# Trusted Producer of Premium Pharmaceutical Injectable Grade Hyaluronic Acid




Type of HA	Quality	General Uses & Types of Products	Barriers to Competition
Pharmaceutical Injectable grade	High Governed by regulatory agencies	<ul> <li>Ophthalmic surgery</li> <li>Joint Injections</li> <li>Bone grafts</li> <li>Intra-articular injections</li> <li>Carrier for drugs</li> <li>Tissue engineering</li> </ul>	High Product specs tailored to needs of end user Heightened quality control in US/EU markets Regulatory barriers to change source
Topical Medical grade	Moderate Governed by regulatory agencies with less restrictions	<ul> <li>Eye drops</li> <li>Topical wound healing</li> <li>Topical medications</li> <li>Intradermal injections</li> </ul>	Moderate
Cosmetic Nutraceuticals	Low Limited or no regulatory agency oversight	<ul><li>Cosmetics, lotions, creams</li><li>Nutraceuticals, supplements</li></ul>	Low to None Commoditized

# Injectable Products Lead Growth in Drug Development Market





## Favorable Anticipated Trends Fuel Long-Term CDMO Demand & Value for Lifecore



Lifecore"

# Long-Term, Blue Chip Customer Base

### **Top 5 Revenue Customers**

## Blue-chip customer base spans:

- 13 commercial customers global and emerging biopharma and biotech companies
- 26 commercial products
- Lifecore continues to expand its presence in the CDMO marketplace by utilizing its specialized capabilities to seek to partner with biopharma and medical device companies

#### **Customers choose Lifecore:**

- Supports all phases of development and commercial lifecycle
- Strong capabilities in manufacturing and supplying pharmaceutical-grade HA in bulk form and injectables
- Technical expertise in high viscous solutions and infrastructure to support development of drugs, biologics, medical devices and combination products
- Proven demonstration of sophisticated quality systems with a clean history







23 Projects\* currently in various phases of development



# **Our Existing Project Breakdown**



	Proof of Concept Development	Development	Scale-up	
Number of Projects	5	8	10	
Anticipated Remaining Time to Commercialization*	3-10 years	2-8 years	1-4 years	
Therapeutic Area	Ophthalmic, Metabolic disorders, Non-Opioid Pain	Ophthalmic, Non-Opioid Pain, Aesthetic, Orthopedic, Oncology	Ophthalmic, Respiratory, Veterinary, Non-Opioid Pain	
Drug or Device	3 Drugs, 2 Devices	6 Drugs, 2 Devices	7 Drugs, 3 Devices	
Customer Type	4 Large Pharma, 1 Small	1 Large Pharma, 1 Medium, 5 Small	1 Large Pharma, 1 Medium, 5 Small	
HA & Non HA	4 HA, 1 Non HA	6 HA, 2 Non HA	5 HA, 5 Non HA	

\* Anticipated remaining time to commercialization may be impacted by but not limited to such factors as regulatory timing, FDA approvals, contract negotiations, and capacity limitations. In addition, customers can elect not to pursue a relationship with Lifecore at any time during that process.

## Revenue Potential of Scale-up Late-phase Projects



Annual Product Revenue Potential	# of Projects	Annual Target Revenue Opportunity
>\$10 million	3	\$30 – \$75 million
\$5 - \$10 million	2	\$10 – \$20 million
<\$5 million	5	\$5 – \$25 million

Note: Projects noted above are anticipated to commence between 1 and 4 years. The commercialization of these projects are subject to numerous conditions which may impact the timing and ultimate revenue generation for Lifecore. 16


## Long History of Stable, Sustainable Growth in Commercial Revenue & EBITDA





# Plan to Increase Operational Capacity by FY25





Theoretical target capacity of 22 million units represents fully staffed equipment capacity that is in place today

Current operational capacity of 10 million units which represents available capacity that is managed against known demand; seek to maintain utilization rates of ~80% of operational capacity

Will require continued investment to build operational capacity to meet demand

## **Our FY22 Outlook**





# Meet the Lifecore Team



Highly Experienced Management Team with Deep Industry Expertise & Proven Ability to Execute

Position         President, Lifecore         CFO         VP and General Manager         VP of Corporate Development & Partnerships         VP of Commercial Development & Served in various         CFO         VP and General Manager         VP of Corporate Development & Served in various         Chief Scientific Resources         VP of Human         VP of Operation           Joined Lifecore         1999         2021         2001         2021         2015         1981         2001         2021         2020           Years of Experience         30+         30+         20+         20+         40+         20+         20+         20+           Served in various         Serves as Landec CFO         Serves as Landec         Co-inventor of CFO         Co-in				Ca l		E.				a contraction of the second se
Position     President, Lifecore     CFO     VP and General Manager     Development & Partnerships     Commercial Development & Partnerships     Chiel Scientific Officer and VP     VP of Manager     VP of Operatic       Joined Lifecores     1999     2021     2001     2021     2015     1981     2001     2021     2020       Years of Experience     30+     30+     30+     20+     20+     40+     20+     20+     20+       Prior Experience     Served in various General Manager and VP of Operation     Served in various as CFO, CFO, operation     Served in various as CFO, CFO, operation     Served in various as CFO, CFO, as CFO, CFO, operation     Previously served as CFO, CFO, operation     Previously served as CFO, CFO, as CFO, CFO, operation     Previously served as CFO, CFO, as CFO, CFO, operation     Served in various as CFO, CFO, as CFO, CFO, operation     Previously served as CFO, CFO, as CFO, CFO, operation     Previously served as CFO, CFO, as CFO, CFO, as CFO, CFO, as CFO, CFO, as CFO, CFO, as CFO, CFO, and Ste Lead and Board Member     Previously served as CFO, CFO, as CFO, CFO, and Ste Lead and Board Member     Previously served as CFO, CFO, as CFO, CFO, a	Name									Steve Laninga
Lifecore     1999     2021     2001     2021     2011     2021     2015     1981     2001     2021     2020       Years of Experience     30+     30+     30+     20+     20+     40+     20+     20+     20+       Prior Experience     Served in various General Manager and VP of Operations     Served in various as CEO, CFO, Operations     Served in various as CEO, CFO, operations     Served in various as CEO, CFO, operations     Served in various as CEO, CFO, equilatory Affairs and Board Member of public and     Previously served as CEO, CFO, operations     Served in various as CEO, CFO, operations     Served in various as CEO, CFO, equilatory Affairs and Catalent     Previously served as CEO, CFO, operations     Served in various as CEO, CFO, operations     Served in various as CEO, CFO, operations     Served in various as CEO, CFO, equilatory Affairs     Previously served as CEO, CFO, operations     Served in various and Site Lead at Catalent     Served in various as CEO, CFO, as CEO, CFO, operations     Served in various as CEO, CFO, operat	Position		CFO		Development &	Commercial				VP of Operations
Experience     30+     30+     30+     20+     20+     20+     20+     20+       Prior     Served in various concertaint functions General Manager and VP of Operations     Serves as Landec CFO     Served in various concertaint functions General Manager and VP of Operations     Serves as Landec CFO     Serves as Landec CFO     Served in various concertaint functions as CEO, CFO, Operations     Serves as Landec concertaint functions as CEO, CFO     Served in various concertaint functions as CEO, CFO     Previously served as CEO, CFO     Resources at Development, and Board Member op bublic and     Served in various concertaint functions and Site Lead at Cetaient     Co-inventor of lifecore at lifecores     Previously served as VP of Human Boston Scientifier Bustiness Development at     Previously served as VP of Human Bissurgers Development at     Previously served as VP of Human Bissurgers Controller at Lifecore     Previously served as VP of Human Bissurgers and Site Lead at Perrigo		1999	2021	2001	2021	2015	1981	2001	2021	2020
Prior         CFO         CFO         Lifecore's HÅ         Previously served as VP of Business Development, Dereviously served and VP of Operations         Previously served as VP of Business Previously served as VP of Business Development, Drug Product         Previously served as VP of Business Development at         Previously served as Senior Director Director of New Director of New Development at         Previously served as VP of Business Development at         Previously served as VP of Previously served as Senior Director Development at         Previously served as VP of Previously served as Senior Director Director of New Director of New Development at         Previously served as VP of Previously served as VP of Development at         Previously served as VP of Previously served as Senior Director Director of New Director of New Director of New Development at         Previously served as VP of Previously served as VP of Development at         Previously served as Senior Director Director of New Director of New Director of New Director of New Development at         Previously served as VP of Development at         Previous		30+	30+	30+	20+	20+	40+	20+	20+	20+
		roles at Lifecore including VP and General Manager and VP of	CFO Previously served in executive roles as CEO, CFO, General Counsel and Board Member of public and	roles at Lifecore surrounding Quality Assurance and	as VP of Business Development, Drug Product	as VP of Peripheral Interventions Marketing at	Lifecore's HA fermentation and mfg. process Previously served as Director of New Bustiness Development at	as Senior Director of Finance and Controller at	as VP of Human Resources at	Operations and Site Lead

## **Lifecore Business Highlights**



Fully-integrated CDMO with **highly differentiated capabilities** for development and fill/finish of sterile, injectable-grade pharmaceutical products



A leading provider of premium research grade HA with focus on complex and highly regulated products



Large, growing addressable markets with attractive underlying tailwinds supported by **long-term** customer relationships and low turnover



Aspirational goal to accelerate annual revenue growth into the mid- to high-teens based upon current pipeline characteristics and favorable industry tailwinds in the coming years



Multiple levers to continue to drive **long-term growth**, including continued **expansion and commercialization** of development pipeline



Ø

35+ years of exceptional quality, safety, and regulatory compliance with available capacity & **state-of-the-art** facilities to support future growth



Highly experienced Lifecore management team with deep industry expertise and proven ability to execute

